# A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

> **NCT01489943** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** GSK1605786 500 mg
- **DRUG:** Midazolam 3 mg
- **DRUG:** Pioglitazone 15 mg
- **DRUG:** Omeprazole 40 mg
- **DRUG:** Rosuvastatin 10 mg

## Key facts

- **NCT ID:** NCT01489943
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-19
- **Primary completion:** 2011-11-10
- **Final completion:** 2011-11-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489943, "A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01489943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*